Momentum Grid Report for Electronic Data Capture
Mid-Market Grid Report for Electronic Data Capture
Grid Report for Electronic Data Capture
Momentum scores are based on social, web, employee, and review data that G2 deems influential in a company’s progress. Badges are awarded to products with the top Momentum Grid scores. Products shown in the Mid-Market Grid Report and the Grid Report are ranked by customer satisfaction, based on user reviews, and market presence, based on market share, seller size, and social impact.
Viedoc has earned three exciting slots in the Asia Pacific and India segments:
Asia Regional Grid Report for Electronic Data Capture
Asia Pacific Regional Grid Report for Electronic Data Capture
India Regional Grid Report for Electronic Data Capture
Just like the Momentum and Mid-Market reports above, products shown on the Asia Regional Grid for Electronic Data Capture are also ranked by customer satisfaction and regional market presence. Products in the Leader quadrant are rated highly by G2 users in the Asia region and have substantial Market Presence scores.
Viedoc achieved remarkable success in recent evaluations, securing runner-up positions for the usability of our software solutions and focusing on maintaining positive customer relationships. This impressive performance resulted in twelve recognitions from G2, marking our most substantial acknowledgment from the peer-to-peer website to date.
A trusted source for B2B software reviews, G2 conducts thorough assessments of various software solutions, including EDC systems like Viedoc’s eClinical solution. Rankings are based on genuine user reviews, thus offering valuable insights into user experiences.
These rankings are significant for Viedoc clients and those considering Viedoc for their clinical studies. They reflect not just the quality of our solution but also the reliability, support, and overall value that Viedoc delivers.
A global provider of eClinical software for clinical trials, Viedoc is strategically expanding its presence in several markets to meet increasing demand. With 37% of new global customers in 2023 located in the US, Viedoc aims to capitalize on the rapid growth of the US clinical trials industry, which is expected to surpass $35.1 billion by 2030. The company has experienced a 27% revenue growth in the US over the past 12 months.
To support its expansion, Viedoc has implemented several initiatives, including establishing a US headquarters, appointing a Chief Marketing Officer to strengthen Viedoc's localization efforts in the US market, adapting its data privacy processes to meet US market requirements (by adding a SOC2 assessment to its existing ISO 27001 certification), and scaling up delivery capability with a Software as a Service (SaaS) operational model.
"Data capturing has been made easy because of viedoc, it is incredibly robust and easy to navigate"